Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fresenius Medical Care North America
With
Abbott
Patients with ESRD have a high incidence of acute phase inflammation. Studies have shown that C-reactive Protein (CRP) and interleukin-6 (IL-6) are excellent biomarkers for inflammation, and high levels are predictive of cardiovascular morbidity and mortality in this population. Both uremia and the dialysis process itself contribute to this inflammatory state. It is our hypothesis that paricalcitol therapy decreases the biomarkers of inflammation which may have implications for future studies of morbidity and mortality in this population.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. CKD and receiving hemodialysis for greater than or equal to 3 months
2. Age greater than or equal to 18 years
3. Medically stable
4. AVF or PTFE dialysis access
5. No acute inflammatory disease within 4 weeks prior to study
6. On an average dose of 3 - 7 mcg of paricalcitol three times per week for 4 weeks prior to the study
7. Two consecutive iPTH of 150-400 (biPTH 75 - 200) =/- 30% one week apart
8. Ca \<10.2 mg/dL; PO4 \<7.0
9. Kt/V greater than or equal to 1.2
10. On no other interventional drugs/devices in the past 30 days
You may not be if
1. Currently receiving dialysis using a venous catheter access
2. Currently receiving high dose immunosuppressive therapy (greater than or equal to 10 mg prednisone)
3. Pregnancy
4. Hospitalization within the last 4 weeks. -
Clareo Health | Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients
